BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Multiple Sclerosis, Secondary Progressive

In brief

The primary objective of the study is to investigate whether treatment with BG00012 (dimethyl fumarate) compared with placebo slows the accumulation of disability not related to relapses in participants with secondary progressive multiple sclerosis (SPMS). The secondary objective of the study is to assess the effect of BG00012 compared with placebo on patient-reported outcomes, brain atrophy, and cognitive function.

Key facts

Study ID

NCT02430532

Run by

Biogen

People needed

58

Starts

2015-05-01

Expected to finish

2016-01-01

Last updated by the study team

2017-04-26

Who can join

Age: 18 and older, up to 58. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Research Site — Long Beach, California, United States
• Research Site — San Francisco, California, United States
• Research Site — Tampa, Florida, United States
• Research Site — Vero Beach, Florida, United States
• Research Site — Charlotte, North Carolina, United States
• Research Site — Willow Grove, Pennsylvania, United States
• Research Site — Round Rock, Texas, United States
• Research Site — Brussels, Belgium
• Research Site — Brno, Czechia
• Research Site — Hradec Králové, Czechia
• Research Site — Sittard-Geleen, Netherlands
• Research Site — Gdansk, Poland
• Research Site — Katowice, Poland
• Research Site — Krakow, Poland
• Research Site — Lodz, Poland
• Research Site — Plewiska, Poland
• Research Site — Poznan, Poland
• Research Site — Banská Bystrica, Slovakia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.